Potential of nanostructured lipid carriers in oral delivery of the poorly soluble drugs
Source abstract
Abstract
Abstract The oral route is one of the most preferred routes of administration because of its convenience and safety. Nanostructured lipid carriers (NLCs) are the second-generation nanosize solid lipid nanocarriers that are composed of solid lipids, liquid lipids, and surfactants. The lipid matrix of NLCs has an imperfect structure which allows more drug loading. Other advantages offered by NLCs include biocompatibility, biodegradability, and high encapsulation efficiency. They are considered potential nanocarriers in oral drug delivery and have particle size in the range of 50–300 nm. NLCs have shown improved oral bioavailability of lipophilic drugs. They also bypass first-pass metabolism and inhibit the P-glycoprotein (P-gp) efflux mechanism of drugs. This review mainly highlights the role of NLCs in the oral delivery of drugs and different barriers that have to be overcome to achieve drug delivery by oral route. Graphical abstract
Source: expertdata · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advancements in Transdermal Drug Delivery · Lipid Membrane Structure and Behavior · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Hunter AC, Elsom J, Wibroe PP, Moghimi SM (2012) Polymeric particulate technologies for oral drug delivery and targeting: a pathophysiological perspective. Nanomedicine 1:S15–S20
2. Cheng Y, Xu Z, Ma M, Xu T (2008) Dendrimers as drug carriers: applications in different routes of drug administration. J Pharm Sci 97:123–14310.1002/jps.21079 ↗
3. Sao R, Vaish R, Sinha N (2015) Multifunctional drug delivery systems using inorganic nanomaterials: a review. J Nanosci Nanotechnol 15:1960–197210.1166/jnn.2015.9761 ↗
4. Enayati-Fard R, Akbari J, Saeedi M, Morteza-Semnani K, Morad H, Nokhodchi A (2019) Preparation and characterization of atenolol microparticles developed by emulsification and solvent evaporation. Lat Am J Pharm 38:1342–1349
5. Subramanian S, Singireddy A, Krishnamoorthy K (2012) Nanosponges: a novel class of drug delivery system – review. J Pharm Pharm Sci 15:103–11110.18433/J3K308 ↗
6. Fang CL, Al-Suwayeh SA, Fang JY (2013) Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent Pat Nanotechnol 7:41–5510.2174/187221013804484827 ↗
7. Mukherjee S, Ray S, Thakur RS (2009) Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci 71:349–35810.4103/0250-474X.57282 ↗
8. Silva AC, Santos D, Ferreira D, Lopes CM (2012) Lipid-based nanocarriers as an alternative for oral delivery of poorly water-soluble drugs: peroral and mucosal routes. Curr Med Chem 19:4495–451010.2174/092986712803251584 ↗
9. Souto EB, Doktorovova S (2009) Chapter 6 – Solid lipid nanoparticle formulations pharmacokinetic and biopharmaceutical aspects in drug delivery. Methods Enzymol 464:105–12910.1016/S0076-6879(09)64006-4 ↗
10. Das S, A. Chaudhury A (2011) Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS Pharm Sci Tech 12: 62–7610.1208/s12249-010-9563-0 ↗
11. Müller RH, Radtke M, Wissing SA (2002) Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 242:121–12810.1016/S0378-5173(02)00180-1 ↗
12. Muchow M, Maincent P, Muller RH (2008) Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev Ind Pharm 34:1394–140510.1080/03639040802130061 ↗
13. Shidhaye SS, Vaidya R, Sutar S, Patwardhan A, Kadam VJ (2008) Solid lipid nanoparticles and nanostructured lipid carriers-innovative generations of solid lipid carrier. Curr Drug Deliv 5:324–33110.2174/156720108785915087 ↗
14. Pardeike J, Hommoss A, Muller RH (2009) Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 366:170–18410.1016/j.ijpharm.2008.10.003 ↗
15. Liu CH, Wu CT (2010) Optimization of nanostructured lipid carriers for lutein delivery. Colloid Surf A Physicochem Eng Asp 353:149–15610.1016/j.colsurfa.2009.11.006 ↗
16. Muller R, Radtke M, Wissing S (2002) Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 54:S131–S15510.1016/S0169-409X(02)00118-7 ↗
17. Luo Q, Zhao J, Zhang X, Pan W (2011) Nanostructured lipid carrier (NLC) coated with chitosan oligosaccharides and its potential use in ocular drug delivery system. Int J Pharm 403:185–19110.1016/j.ijpharm.2010.10.013 ↗
18. Davda J, Labhasetwar V (2002) Characterization of nanoparticle uptake by endothelial cells. Int J Pharm 233:51–5910.1016/S0378-5173(01)00923-1 ↗
19. Gupta AK, Gupta M, Yarwood SJ, Curtis AS (2004) Effect of cellular uptake of gelatin nanoparticles on adhesion, morphology and cytoskeleton organisation of human fibroblasts. J Control Release 95:197–20710.1016/j.jconrel.2003.11.006 ↗
20. Zhang XG, Miao J, Dai YQ, Du YZ, Yuan H, Hu FQ (2008) Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells. Int J Pharm 361:239–24410.1016/j.ijpharm.2008.06.002 ↗
21. Li Q, Cai T, Huang Y, Xia X, Cole S, Cai Y (2017) A review of the structure, preparation, and application of NLCs, PNPs, and PLNs. Nanomaterials 7:1–2510.3390/nano7060122 ↗
22. Tiwari R, K Pathak K (2011) Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int J Pharm 415:232–24310.1016/j.ijpharm.2011.05.044 ↗
23. Zhuang CY, Li N, Wang M, Zhang XN, Pan WS, Peng JJ (2010) Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm 394:179–18510.1016/j.ijpharm.2010.05.005 ↗
24. Araújo J, Gonzalez E, Egea MA, Garcia ML, Souto EB (2009) Nanomedicines for ocular NSAIDS: safety on drug delivery. Nanomedicine 5:394–40110.1016/j.nano.2009.02.003 ↗
25. Joshi MD, Müller RH (2009) Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm 71:161–17210.1016/j.ejpb.2008.09.003 ↗
26. Salvi VR, Pawar P (2019) Nanostructured lipid carriers (NLC) system: a novel drug targeting carrier. J Drug Deliv Sci Technol 51:255–26710.1016/j.jddst.2019.02.017 ↗
27. Selvamuthukumar S, Velmurugan R (2012) Nanostructured lipid carriers: a potential drug carrier for cancer chemotherapy. Lipids Health Dis 159:1–8
28. Mitri K, Shegokar R, Gohla S, Anselmi C, Müller RH (2011) Lipid nanocarriers for dermal delivery of lutein: preparation, characterization, stability and performance. Int J Pharm 414:267–27510.1016/j.ijpharm.2011.05.008 ↗
29. Doktorovová S, Araújo J, Garcia ML, Rakovský E, Souto EB (2010) Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC). Colloids Surf B Biointerfaces 75:538–54210.1016/j.colsurfb.2009.09.033 ↗
30. Radtke M, Müller RH (2001) Nanostructured lipid drug carriers. New Drugs 2:48–52
31. Tamjidi F, Shahedi M, Varshosaz J, Nasirpour A (2013) Nanostructured lipid carriers (NLC): a potential delivery system for bioactive food molecules. Innov Food Sci Emerg Technol 19:29–4310.1016/j.ifset.2013.03.002 ↗
32. Gonzalez-Mira E, Egea MA, Garcia ML, Souto EB (2010) Design and ocular tolerance of flurbiprofen loaded ultrasound engineered NLC. Colloids Surf B Biointerfaces 81:412–42110.1016/j.colsurfb.2010.07.029 ↗
33. Kelidari HR, Moazeni M, Babaei R, Saeedi M, Akbari J, Parkoohi PI (2017) Improved yeast delivery of fluconazole with a nanostructured lipid carrier system. Biomed Pharmacother 89:83–8810.1016/j.biopha.2017.02.008 ↗
34. Kudarha R, Dhas NL, Pandey A, Belgamwar VS, Ige PP (2015) Box-Behnken study design for optimization of bicalutamide loaded nanostructured lipid carrier: stability assessment. Pharm Dev Technol 20:608–61810.3109/10837450.2014.908305 ↗
35. Garcia-Orue I, Gainza G, Girbau C, Alonso R, Aguirre JJ, Pedraz JL (2016) LL37 loaded nanostructured lipid carriers (NLC): a new strategy for the topical treatment of chronic wounds. Eur J Pharm Biopharm 108:310–31610.1016/j.ejpb.2016.04.006 ↗
36. Ferreira M, Chaves LL, Lima SA, Reis S (2015) Optimization of nanostructured lipid carriers loaded with methotrexate: a tool for inflammatory and cancer therapy. Int J Pharm 492:65–7210.1016/j.ijpharm.2015.07.013 ↗
37. Monteiro LM, Lobenberg R, Cotrim PC, Barros de Araujo GL, Bou-Chacra N (2017) Buparvaquone nanostructured lipid carrier: development of an affordable delivery system for the treatment of leishmaniases. Biomed Res Int:1–1110.1155/2017/9781603 ↗
38. Gramdorf S, Hermann S, Hentschel A, Schrader K (2008) Crystallized miniemulsions: influence of operating parameters during high-pressure homogenization on size and shape of particles. Colloids Surf A Physicochem Eng Asp 331:108–11310.1016/j.colsurfa.2008.07.016 ↗
39. Attama A, Anthony A, Mumuni A, Momoh A, Philip F (2012) Lipid nanoparticulate drug delivery systems: a revolution in dosage form design and development. In: Sezer D (ed) Recent advances in novel drug carrier systems. IntechOpen, pp 107–140
40. Kaur S, Nautyal U, Singh R, Singh S, Devi A (2015) Nanostructure lipid carrier (NLC): the new generation of lipid nanoparticles. Asian Pac J Health Sci 2:76–9310.21276/apjhs.2015.2.2.14 ↗
41. Manjunath K, Venkateswarlu V (2005) Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release 107:215–22810.1016/j.jconrel.2005.06.006 ↗
42. Sivaramakrishnan R, Nakamura C, Mehnert W, Korting HC, Kramer KD, Schäfer-Korting M (2004) Glucocorticoid entrapment into lipid carriers – characterisation by parelectric spectroscopy and influence on dermal uptake. J Control Release 97:493–50210.1016/S0168-3659(04)00169-5 ↗
43. Puri A, Loomis K, Smith B, Lee JH, Yavlovich A, Heldman E (2009) Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst 26:523–58010.1615/CritRevTherDrugCarrierSyst.v26.i6.10 ↗
44. Pyo Y-C, Tran P, Kim D-H, Park J-S (2020) Chitosan-coated nanostructured lipid carriers of fenofibrate with enhanced oral bioavailability and efficacy. Colloids Surf B Biointerfaces 196:1–910.1016/j.colsurfb.2020.111331 ↗
45. Yunjing Z, Xue L, Cong L, Yihan K, Xing T, Yu Z (2020) Nanostructured lipid carriers as oral delivery systems for improving oral bioavailability of nintedanib by promoting intestinal absorption. Int J Pharm 586:1–11
46. Chahinez H, David A, Kamalinder KS (2020) Impact of liquid lipid on development and stability of trimyristin nanostructured lipid carriers for oral delivery of resveratrol. J Mol Liq 316:1–57
47. Rania KE, Sa D, Ebtessam AE, Gamal EM, Mona FA (2020) Chitosan coated nanostructured lipid carriers for enhanced in vivo efficacy of albendazole against Trichinella spiralis. Carbohydr Polym 232:11582610.1016/j.carbpol.2019.115826 ↗
48. Archu S, Yub N, Bharti M, Kanchan K (2019) Nanostructured lipid carriers for oral bioavailability enhancement of exemestane: formulation design, in vitro, ex vivo, and in vivo studies. J Pharm Sci 108:3382–339510.1016/j.xphs.2019.06.003 ↗
49. Üner M (2015) Characterization and imaging of solid lipid nanoparticles and nanostructured lipid carriers. In: Aliofkhazraei M (ed) Handbook of nanoparticles. Springer, New York, pp 117–141
50. Mehnert W, Mäder K (2012) Solid lipid nanoparticles: productión, characterization and applications. Adv Drug Deliv Rev 64:83–10110.1016/j.addr.2012.09.021 ↗
51. Harshita BMA, Rizwanullah M, Beg S, Pottoo FH, Siddiqui S et al (2019) Paclitaxel-loaded nanolipidic carriers with improved oral bioavailability and anticancer activity against human liver carcinoma. AAPS PharmSciTech 20:87–10410.1208/s12249-019-1304-4 ↗
52. Rizwanullah M, Amin S, Ahmed J (2017) Improved pharmacokinetics and antihyperlipidemic efficacy of rosuvastatin loaded nanostructured lipid carriers. J Drug Target 25:58–7810.1080/1061186X.2016.1191080 ↗
53. Gaba B, Fazil M, Khan S, Ali A, Baboota S, Ali J (2015) Nanostructured lipid carrier system for topical delivery of terbinafine hydrochloride. Bull Fac Pharm Cairo Univ 53:147–159
54. Lin WJ, Duh YS (2016) Nanostructured lipid carriers for transdermal delivery of acid labile lansoprazole. Eur J Pharm Biopharm 108:297–30310.1016/j.ejpb.2016.07.015 ↗
55. Shahgaldian P, DaSilva E, Coleman AW, Rather B, Zaworotko MJ (2003) Para-acyl-calix-arene based solid lipid nanoparticles (SLNs): a detailed study of preparation and stability parameters. Int J Pharm 253:23–3810.1016/S0378-5173(02)00639-7 ↗
56. Patel M, Souto EB, Singh KK (2013) Advances in brain drug targeting and delivery: limitations and challenges of solid lipid nanoparticles. Expert Opin Drug Deliv 10:889–90510.1517/17425247.2013.784742 ↗
57. Zhu Y, Liang X, Lu C, Kong Y, Tang X, Zhang Y et al (2020) Nanostructured lipid carriers as oral delivery systems for improving oral bioavailability of nintedanib by promoting intestinal absorption. Int J Pharm 586:11956910.1016/j.ijpharm.2020.119569 ↗
58. Xu R (2008) Progress in nanoparticles characterization: sizing and zeta potential measurement. Particuology 6:112–11510.1016/j.partic.2007.12.002 ↗
59. Harisa GI, Alomrani AH, Badran MM (2017) Simvastatin-loaded nanostructured lipid carriers attenuate the atherogenic risk of erythrocytes in hyperlipidemic rats. Eur J Pharm Sci 96:62–7110.1016/j.ejps.2016.09.004 ↗
60. Qian Z, Haifeng Y, Benazir S, Xinyu L, Lin P, Xiuge G (2020) Nanostructured lipid carriers with exceptional gastrointestinal stability and inhibition of p-gp efflux for improved oral delivery of tilmicosin. Colloids Surf B Biointerfaces 187:11064910.1016/j.colsurfb.2019.110649 ↗
61. Xie S, Pan B, Wang M, Zhu L, Wang F, Dong Z (2010) Formulation, characterization and pharmacokinetics of praziquantel-loaded hydrogenated castor oil solid lipid nanoparticles. Nanomedicine 5:693–70110.2217/nnm.10.42 ↗
62. Anton N, Benoit JP, Saulnier P (2008) Design and production of nanoparticles formulated from nano-emulsion templates-a review. J Control Release 128:185–19910.1016/j.jconrel.2008.02.007 ↗
63. Zhang J, Fan Y, Smith E (2009) Experimental design for the optimization of lipid nanoparticles. J Pharm Sci 98:1813–181910.1002/jps.21549 ↗
64. Hu FQ, Jiang SP, Du YZ, Yuan H, Ye YQ, Zeng S (2006) Preparation and characteristics of monostearin nanostructured lipid carriers. Int J Pharm 314:83–8910.1016/j.ijpharm.2006.01.040 ↗
65. Han F, Li S, Yin R, Liu H, Xu L (2008) Effect of surfactants on the formation and characterization of a new type of colloidal drug delivery system: nanostructured lipid carriers. Colloids Surf A Physicochem Eng Asp 315:210–21610.1016/j.colsurfa.2007.08.005 ↗
66. Müller RH, Mäder K, Gohla S (2000) Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 50:161–17710.1016/S0939-6411(00)00087-4 ↗
67. Gönüllü U, Üner M, Yener G, Karaman EF, Aydoğmuş Z (2015) Formulation and characterization of solid lipid nanoparticles, nanostructured lipid carriers and nanoemulsion of lornoxicam for transdermal delivery. Acta Pharm 65:1–1310.1515/acph-2015-0009 ↗
68. Shah R, Eldridge D, Palombo E, Harding I (2015) Lipid nanoparticles: production, characterization and stability. Springer, London10.1007/978-3-319-10711-0 ↗
69. Castelli F, Puglia C, Sarpietro MG, Rizza L, Bonina F (2005) Characterization of indomethacin-loaded lipid nanoparticles by differential scanning calorimetry. Int J Pharm 304:231–23810.1016/j.ijpharm.2005.08.011 ↗
70. Bunjes H, Steiniger F, Richter W (2007) Visualizing the structure of triglyceride nanoparticles in different crystal modifications. Langmuir 23:4005–401110.1021/la062904p ↗
71. de Mendoza AEH, Rayo M, Mollinedo F, Blanco-Prieto MJ (2008) Lipid nanoparticles for alkyl lysophospholipid edel-fosine encapsulation: development and in vitro characterization. Eur J Pharm Biopharm 68:207–21310.1016/j.ejpb.2007.06.015 ↗
72. Crucho CIC, Barros MT (2017) Polymeric nanoparticles: a study on the preparation variables and characterization methods. Mater Sci Eng C 80:771–78410.1016/j.msec.2017.06.004 ↗
73. Joshi M, Patravale V (2008) Nanostructured lipid carrier based gel of celecoxib. Int J Pharm 346:124–13210.1016/j.ijpharm.2007.05.060 ↗
74. Muller R, Mader K, Lippacher A, Jenning V (2000) Solid-liquid (semi-solid) liquid particles and method of producing highly concentrated lipid particle dispersions. German Patent Application, 199.
75. Fang G, Tang B, Chao Y, Xu H, Gou J, Zhang Y (2015) Cysteine functionalized nanostructured lipid carriers for oral delivery of docetaxel: a permeability and pharmacokinetic study. Mol Pharm 12:2384–239510.1021/acs.molpharmaceut.5b00081 ↗
76. Elmowafy M, Shalaby K, Badran MM, Ali HM, Abdel-Bakky MS, Ibrahim HM (2018) Multifunctional carbamazepine loaded nanostructured lipid carrier (NLC) formulation. Int J Pharm 550:359–37110.1016/j.ijpharm.2018.08.062 ↗
77. Shevalkar G, Vavia P (2019) Solidified nanostructured lipid carrier (S-NLC) for enhancing the oral bioavailability of ezetimibe. J Drug Deliv Sci Technol 53:10121110.1016/j.jddst.2019.101211 ↗
78. Fang YP, Lin YK, Su YH, Fang JY (2011) Tryptanthrin-loaded nanoparticles for delivery into cultured human breast cancer cells, Mcf7: the effects of solid lipid/liquid lipid ratios in the inner core. Chem Pharm Bull 59:266–27110.1248/cpb.59.266 ↗
79. Jenning V, Thunemann AF, Gohla SH (2000) Characterization of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm 199:167–17710.1016/S0378-5173(00)00378-1 ↗
80. Thapa C, Ahad A, Aqil M, Imam SS, Sultana Y (2018) Formulation and optimization of nanostructured lipid carriers to enhance oral bioavailability of telmisartan using Box Behnken design. J Drug Deliv Sci Technol 44:431–43910.1016/j.jddst.2018.02.003 ↗
81. Schäfer-Korting M (2010) Drug delivery. In: Handbook of experimental pharmacology. Springer, Berlin
82. Shah MK, Khatri P, Vora N, Patel NK, Jain S, Lin S (2019) Lipid nanocarriers: preparation, characterization and absorption mechanism and applications to improve oral bioavailability of poorly water-soluble drugs. In: Grumezescu AM (ed) Biomedical applications of nanoparticles. William Andrew Publisher, Norwich, pp 117–14710.1016/B978-0-12-816506-5.00003-6 ↗
83. Boyd BJ, Bergström CAS, Vinarov Z, Kuentz M, Brouwers J, Augustijns P (2019) Successful oral delivery of poorly water-soluble drugs both depends on the intraluminal behavior of drugs and of appropriate advanced drug delivery systems. Eur J Pharm Sci 137:1–2710.1016/j.ejps.2019.104967 ↗
84. Knipe JM, Chen F, Peppas NA (2015) Enzymatic biodegradation of hydrogels for protein delivery targeted to the small intestine. Biomacromolecules 16:962–97210.1021/bm501871a ↗
85. Ensign LM, Cone R, Hanes J (2012) Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev 64:557–57010.1016/j.addr.2011.12.009 ↗
86. Farokhzad OC, Langer R (2009) Impact of nanotechnology on drug delivery. ACS Nano 3:16–2010.1021/nn900002m ↗
87. Bernkop-Schnurch A (2013) Nanocarrier systems for oral drug delivery: do we really need them? Eur J Pharm Sci 49:272–27710.1016/j.ejps.2013.03.008 ↗
88. Park S, Garcia C, Shin G, Kim J (2017) Development of nanostructured lipid carriers for the encapsulation and controlled release of vitamin D3. Food Chem 225:213–21910.1016/j.foodchem.2017.01.015 ↗
89. Singh R, Lillard JW (2008) Past, present, and future technologies for oral delivery of herapeutic proteins. J Pharm Sci 97:2497–242310.1002/jps.21183 ↗
90. Homayun B, Lin X, Choi HJ (2019) Challenges and recent progress in oral drug delivery systems for biopharmaceuticals. Pharmaceutics 11:1–2910.3390/pharmaceutics11030129 ↗
91. Zhang R, McClements DJ (2018) Characterization of gastrointestinal fate of nanoemulsions. In: Jafari SM, McClements DJ (eds) Nanoemulsions. Elsevier Inc, USA, pp 577–61210.1016/B978-0-12-811838-2.00018-7 ↗
92. Brown TD, Whitehead KA, Mitragotri S (2020) Materials for oral delivery of proteins and peptides. Nat Rev Mater 5:127–14810.1038/s41578-019-0156-6 ↗
93. Moreno MR, Qi P, Wong YS, Xiong MG, Zhang Y, Venkatraman S (2019) Polymeric nanomaterials: methods of preparation and characterization. In: Mohapatra S, Ranjan S, Dasgupta N, Mishra R, Thomas S (eds) Nanocarriers for drug delivery. Elsevier, USA, pp 557–55310.1016/B978-0-12-814033-8.00018-7 ↗
94. Kiptoo P, Calcagno AM, Siahaan TJ (2016) Physiological, biochemical, and chemical barriers to oral drug delivery. In: Wang B, Hu L (eds) Drug delivery. John Wiley & Sons, New York, pp 19–3410.1002/9781118833322.ch2 ↗
95. Poovi G, Damodharan N (2018) Lipid nanoparticles: a challenging approach for oral delivery of BCS class-II drugs. Fut. J Pharm Sci 4:191–205
96. Bummer PM (2004) Physical chemical considerations of lipid based oral drug delivery solid lipid NPs. Critical Rev Thera Drug Carrier Sys 21:1–1910.1615/CritRevTherDrugCarrierSyst.v21.i1.10 ↗
97. Andrysek T (2003) Impact of physical properties of formulations on bioavailability of active substance: current and novel drugs with cyclosporine. Mol Immunol 39:1061–106510.1016/S0161-5890(03)00077-4 ↗
98. Andrysek T (2006) Excipients and their role in absorption: influencing bioavailability of cyclosporine by triglycerides and polyglycerol esters. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 150:227–23310.5507/bp.2006.032 ↗
99. Tan JS, Roberts CJ, Billa N (2018) Mucoadhesive chitosan-coated nanostructured lipid carriers for oral delivery of amphotericin B. Pharmaceut Dev Technol 24:504–512
100. Tian C, Asghar S, Wu Y, Amerigos DK, Chen Z, Zhang M (2017) N-acetyl-L-cysteine functionalized nanostructured lipid carriers for improving oral bioavailability of curcumin: preparation, in vitro and in vivo evaluations. Drug Deliv 24:1605–161610.1080/10717544.2017.1391890 ↗